All News
Future treatment for #AxSpA ?
Promising data for #Bimekizumab
Inhibits IL-17 A and F
#RNL2023 https://t.co/H2euMPgIFj
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Dr. John Reveille on genetic sharing between AS, PsO, and IBD
- multiple overlapping genetic signals
@RheumNow #RNL2023 https://t.co/p3gvfTO732
Robert B Chao, MD doctorRBC ( View Tweet)
Late onset Inflammatory back pain?, Reveille #RNL2023 @RheumNow https://t.co/G0LOgjmBvj
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Reassuring data by Dr. Laurent Arnaud on HCQ
- arrhythmia risk from HCQ similar to general population
@RheumNow #RNL2023 https://t.co/vMDg2SlbJQ
Robert B Chao, MD doctorRBC ( View Tweet)
Great tips for #AxSpA monitoring
and
🚩 red flags for radiographic progression 🚩
❌No need for routine imaging follow-up
#RNL2023 @deodhara https://t.co/PAFtHIrqRF
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
https://t.co/MwruMhmvPq https://t.co/WnCvCZtq6z
Links:
Dr. John Cush RheumNow ( View Tweet)
Is AS transmission to offspring more common from the mother or father?
- hard to say, some studies (including Swiss and UK studies) show mothers play a larger role
- other studies show fathers do
@RheumNow #RNL2023 https://t.co/Vr1qUy5Y6b
Robert B Chao, MD doctorRBC ( View Tweet)
AxSpA is primarily a genetic disease
- clusters in families, especially HLA-B27+ first degree relatives
- genetic testing for asymptomatic relatives not recommended
@RheumNow #RNL2023 https://t.co/vhBlNlXMHR
Robert B Chao, MD doctorRBC ( View Tweet)
New download available!
VTE Risks and JAK inhibition
https://t.co/TCt4PcySYr https://t.co/wBaEsC3Wry
Links:
Dr. John Cush RheumNow ( View Tweet)
BEAT LUPUS trial results showed that belimumab after RTX reduced dsDNA levels/flaring. Questions remain if this can be a successful combination in lupus nephritis. Dr. Kalunian #RNL2023 @RheumNow https://t.co/XeuybrWigf
Dr. Rachel Tate uptoTate ( View Tweet)
"I think rheumatologists are great observers, they just need to try meds." Dr. Furie regarding new medications/indications in rheumatology. #RNL2023 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Awareness increased for this disease , BY Atul Deodhar #RNL2023 @RheumNow https://t.co/MSBrYU5Pb4
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#RNL2023 @RheumNow
Atul Deodhar:
Prevalence of AS is increasing!
Is it truly more? Or likely better recognized and diagnosed, as well as increased recognition of nr-AxSpa https://t.co/qNwUg5RtaG
Eric Dein ericdeinmd ( View Tweet)
Atul Deodhar's "3-4-5" Rule for MRI Sacroiliac Jts (SIJ)
Erosion in 3+ SIJ quadrants
Bone marrow edema 4+ SIJ quadrants
Fat lesion in 5+ SI joint
@Rheumnow #RNL2023 https://t.co/AHZUhhEmmC
Eric Dein ericdeinmd ( View Tweet)
Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS.
*Erosions in 3 or more SIJ quadrants
*BME in 4 or more SIJ quadrants
*Fat lesions in 5 of more SIJ quadrants
#RNL2023 @RheumNow https://t.co/2m8TmkQo0A
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Atul Deodhar on AxSpA
- 5-40% of nr-axSpA progress to r-axSpA over 2-10 years
- is non-radiographic axSpA a misnomer?
@RheumNow #RNL2023 https://t.co/bhwlbg6eWN
Robert B Chao, MD doctorRBC ( View Tweet)
Risk factors for radiographic progression:
Men ♂️
Smoking 🚬
Active inflammation🔥
Blue collar workers 💪
HLA-B27+ 💉
Pre-existing syndesmophyte 🩻
Atul Deodhar at #RNL2023 @RheumNow https://t.co/9ibHTEhi9k
Eric Dein ericdeinmd ( View Tweet)
No significance difference in radiographic progression in patients with IL17-TNF , BY Atul Deodhar #RNL2023 @RheumNow https://t.co/S3NQ4mWgjt
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
SURPASS: SEC vs ADA for axSpA
Outcome: %pts with no radiographic progression
Not benefit- Secukinumab not better than adalimumab
Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well!
@RheumNow #RNL2023 https://t.co/Vt58jSXCMd
Eric Dein ericdeinmd ( View Tweet)
First Head-to-Head bDMARD study in axSpA to assess radiographic progression
- secukinumab vs. adalimumab biosimilar
- 66% of either arm prevented radiographic progression
- no difference between two arms but good news is radiographic progression is low!
@RheumNow #RNL2023 https://t.co/xq8GhN7kzr
Robert B Chao, MD doctorRBC ( View Tweet)